Buruli ulcer

  • Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer
    Experimental Therapeutics
    Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer

    Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against Mycobacterium ulcerans infection in mice but has dose- and duration-dependent...

    Deepak V. Almeida, Till F. Omansen, Si-Yang Li, Jin Lee, Jacques H. Grosset, Paul J. Converse, Eric L. Nuermberger
  • High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of <span class="named-content genus-species" id="named-content-1">Mycobacterium ulcerans</span> Disease
    Experimental Therapeutics
    High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease

    Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue infection that is associated with disability and social stigma. The mainstay of BU treatment is an 8-week course of rifampin (RIF) at 10 mg/kg of body weight and 150 mg/kg streptomycin (STR).

    Till F. Omansen, Deepak Almeida, Paul J. Converse, Si-Yang Li, Jin Lee, Ymkje Stienstra, Tjip van der Werf, Jacques H. Grosset, Eric L. Nuermberger
Back to top